Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD20 CAR T cells LUCAR-20SP

A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20SP specifically recognize and kill CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic anti-CD20 CAR-T cells LUCAR-20SP
Code name:	LUCAR 20SP LUCAR-20SP LUCAR20SP

allogeneic anti-CD20 CAR T cells LUCAR-20SP

Search NCI's Drug Dictionary